Is 0.02 PSA Considered Undetectable?

A PSA of 0.02 ng/mL is generally considered undetectable or at the very floor of what current blood tests can reliably measure, but the honest answer depends on which laboratory ran your test. Some labs set their “undetectable” threshold at 0.02 ng/mL or below, while others use 0.05 ng/mL as the cutoff. That distinction matters because a reading of 0.02 at one lab means “we found nothing,” while the same number at another lab technically qualifies as a measurable result. For most men tracking PSA after prostate cancer treatment, a value this low is reassuring, but understanding what the number actually represents requires a closer look at assay technology, clinical thresholds, and what drives PSA levels at the bottom of the scale.

Why There Is No Single Definition of “Undetectable”

The confusion starts with the fact that different laboratories use different PSA assays, and each assay has its own lower detection limit. Standard PSA tests typically bottom out at around 0.1 ng/mL. Ultrasensitive PSA (uPSA) assays push that floor much lower, sometimes to 0.01 ng/mL or even below. When your lab report says “undetectable,” it means the result fell below whatever threshold that particular assay can reliably measure. It does not mean your blood contains zero PSA protein.

A large study tracking outcomes after radical prostatectomy defined undetectable uPSA as 0.05 ng/mL or below, specifically because the PSA data came from multiple laboratories with different reporting floors. Some of those labs defined undetectable at 0.02, others at 0.05, and the researchers used the higher cutoff to keep comparisons fair across the dataset.¹ This is a good illustration of why a single number like 0.02 doesn’t have one universal meaning. Your report might say “<0.02" (meaning undetectable below that threshold), "0.02" (meaning the assay detected exactly that amount), or "undetectable" with a footnote explaining the lab's cutoff. Each of those scenarios carries a slightly different clinical flavor.

The manufacturer’s stated detection limit also isn’t the final word. The analytic detection limit is determined under ideal conditions, but human blood contains proteins and other molecules that can interfere with the measurement. The biologic lower detection limit, which accounts for those interferences, tends to be higher than what the manufacturer advertises.² So even with an ultrasensitive assay, readings at the very bottom of the range come with a wider margin of uncertainty than readings in the middle of the scale.

What Biochemical Recurrence Actually Means and Where 0.02 Fits

After radical prostatectomy, the widely used threshold for biochemical recurrence is a PSA of 0.2 ng/mL or higher. After radiation therapy, the Phoenix criteria set the bar even higher, at 2.0 ng/mL above the lowest PSA level reached after treatment.³ A PSA of 0.02 sits far below both of these thresholds, which is why, in standard clinical terms, it does not meet the definition of recurrence.

That said, there is no universal agreement on the best PSA cutoff for declaring recurrence. Some researchers and clinicians have argued the 0.2 threshold is too high, because by the time PSA reaches that level, cancer may have had more time to establish itself. Roughly 20 to 40 percent of men who undergo radical prostatectomy eventually develop biochemical recurrence, and PSA remains the primary tool for catching it, yet the field has not settled on one perfect number.⁴ What this means for you at 0.02 is that you are well within the “favorable” zone by any current standard. The number becomes more meaningful over time, as your doctor tracks whether it stays flat, drifts upward, or drops further.

Why the Nadir Matters More Than a Single Reading

The lowest PSA level you reach after surgery, called the nadir, is one of the strongest predictors of long-term outcomes. Research using ultrasensitive assays has identified a nadir of 0.01 ng/mL as an optimal cutoff for sorting men into lower-risk and higher-risk groups. Men whose PSA dropped to 0.01 or below had roughly an 80 percent chance of remaining free of biochemical recurrence within the first three years, compared to a 20 percent recurrence risk in men whose PSA never fell that low.⁵ Reaching that very low floor is a strong positive signal, and 0.02 is close to it.

An undetectable nadir has also been shown to be an independent predictor of recurrence-free survival, alongside factors like the pre-surgery PSA, pathologic stage, and Gleason score.⁶ In other words, a very low nadir is good news even after adjusting for how aggressive the cancer was. Men who reach an undetectable nadir after surgery have the best long-term recurrence-free survival regardless of how quickly they got there, whereas men whose PSA remains detectable, even at low levels, face a progressively higher risk, especially if the detectable value appears early.⁷

Beyond the first few years, the pattern of ultrasensitive PSA readings over time actually predicts recurrence more accurately than the nadir alone. For recurrence beyond five years after surgery, the trajectory of uPSA values outperformed the initial nadir as a predictor.⁵ This is why your doctor cares less about any single PSA reading and more about the trend line across multiple visits.

Can a PSA of 0.02 Come From Benign Tissue?

After radical prostatectomy, the prostate gland is removed, but tiny amounts of benign prostate tissue can remain behind. Biopsies of the urethral stump after surgery have found benign glands in up to 53 percent of specimens, and bladder neck biopsies have shown them in up to 38 percent.⁸ It seems logical that these remnants could leak small amounts of PSA into the bloodstream, potentially explaining a low but detectable reading like 0.02.

However, the evidence suggests this is unlikely to cause a clinically meaningful PSA level. One study found that the presence of benign glandular tissue at the time of surgery was not associated with a higher risk of detectable PSA afterward, nor with biochemical recurrence or disease progression.⁹ Another concluded that retained benign prostatic elements are “an unlikely source of elevated PSA levels” in men who have had the surgery.¹⁰ So while benign tissue remnants are common, they don’t appear to be responsible for pushing PSA into detectable territory in most cases. If your PSA starts climbing, the explanation is more likely to be cancer-related than benign.

PSA Velocity and Doubling Time Tell You More Than the Number Itself

When PSA is very low and begins to rise, the speed of that rise is far more clinically useful than any single value. Two men can both have a PSA of 0.15 ng/mL, but if one’s PSA doubled every six months and the other’s doubled every two years, they face very different situations. Imaging studies have demonstrated this clearly: men with a fast PSA doubling time (around six months) were far more likely to have detectable disease on PET scans, while those with a slower doubling time (around 15 months) were more likely to scan negative.¹¹

At a PSA of 0.02, there isn’t enough of a data trail to calculate velocity or doubling time. That comes later, if the number starts moving. For now, the most useful thing you can do is keep getting tested on the recommended schedule so that if the number does creep upward, your doctor can spot the trend early and measure its speed.

When Salvage Treatment Enters the Picture

One of the practical reasons to pay attention to ultrasensitive PSA, even at very low levels, is that earlier salvage radiation therapy appears to produce better outcomes if recurrence does happen. A large study found that men who received salvage radiation when their PSA was at or below 0.25 ng/mL had significantly lower all-cause mortality compared to those treated at higher PSA values. That survival advantage disappeared at cutoffs below 0.25, suggesting there may be a sweet spot for intervention rather than a “the earlier, the better” rule all the way down to zero.¹²

For men with low persistent or slowly rising PSA after surgery who receive early salvage radiation, outcomes remain encouraging. Recurrence-free survival and overall survival rates are high in this group, and the development of metastases is rare. Higher tumor grade and stage are more predictive of poor outcomes than whether the PSA was persistent versus rising after an initial dip.¹³ The takeaway at a PSA of 0.02 is that you are nowhere near the threshold where salvage treatment is typically considered. But tracking the number carefully means that if you ever do need intervention, you’ll be in a position to act at the most favorable time.

Things That Can Muddy the Numbers

At very low PSA levels, small sources of error loom larger in proportion to the measurement itself. A few things can produce misleading readings:

Heterophilic antibodies: These are antibodies in your blood directed against animal proteins. Because PSA assays use animal-derived antibodies as part of the testing process, heterophilic antibodies can interfere and produce false-positive results.¹⁴ This is rare, but it has been documented as a cause of unexplained, repeated PSA spikes.
Assay variability: Different PSA testing platforms don’t always agree with each other. Quality-control studies have found wide differences in PSA results across methods, particularly when using certain control materials.¹⁵ Switching labs between tests can make it look like your PSA jumped or dropped when it didn’t actually change at all.
5-alpha-reductase inhibitors: Medications like finasteride, sometimes prescribed for hair loss or residual urinary symptoms, can cut PSA levels roughly in half.¹⁶ If you are taking one of these drugs, your doctor needs to know, because a PSA of 0.02 while on finasteride might correspond to a “true” PSA closer to 0.04.

Consistency helps control for these issues. Getting your PSA drawn at the same lab, using the same assay, at regular intervals gives your doctor the clearest possible trend line. One oddball result in an otherwise flat series of readings is more likely noise than signal.

What Advanced Imaging Can and Cannot Do at Low PSA

Newer imaging technologies, particularly PSMA PET/CT scans, have pushed the boundaries of what can be detected at very low PSA levels. A study using extended-field PSMA PET/CT found that even at PSA levels below 0.2 ng/mL, about two-thirds of scans were positive for PSMA-avid disease. Detection rates climbed with rising PSA: 75 percent at PSA 0.2 to 0.5, 84 percent at 0.5 to 1.0, and 95 percent at 1.0 to 2.0.¹⁷

Those numbers are impressive, but they apply to men who were referred for imaging because recurrence was already suspected. A man with a stable PSA of 0.02 after surgery is not the population these scans were evaluated in. Ordering a PSMA PET scan at a PSA of 0.02 with no rising trend would likely produce either a negative scan or a false positive, neither of which is particularly useful. These scans are most valuable when PSA is rising and your medical team is trying to figure out where the recurrence is located so they can target treatment.

Ultra-Low PSA as a Treatment-Response Marker

The significance of a 0.02 reading varies depending on your treatment context. After radical prostatectomy, 0.02 is essentially the goal: it means the surgery appears to have removed all PSA-producing tissue. But in the setting of metastatic hormone-sensitive prostate cancer, achieving an ultra-low PSA of less than 0.02 within the first three months of systemic therapy is emerging as a marker of exceptional treatment response. Research has linked reaching that threshold early to prolonged progression-free survival, suggesting it could serve as an early indicator that the treatment regimen is working well.¹⁸

This is a newer area of research, and the idea of using ultra-low PSA as a surrogate endpoint for treatment success hasn’t been fully validated yet. But it underscores that 0.02 is increasingly treated not just as “undetectable” but as a meaningful biological marker in its own right, one that may eventually help guide treatment decisions across different stages of the disease.

The Emotional Weight of PSA Monitoring

The clinical reassurance that 0.02 is an excellent number doesn’t always translate into emotional peace of mind. PSA anxiety, sometimes called PSAdynia, is a recognized phenomenon among prostate cancer patients. It describes the physical and emotional distress that builds around PSA testing and results. The anxiety can spike in the days before a scheduled blood draw and persist until the results come back, sometimes affecting daily life, sleep, and how men interpret unrelated physical symptoms.¹⁹

Ultrasensitive assays, for all their clinical utility, may amplify this anxiety by reporting tiny fluctuations that earlier assays would have lumped together as “undetectable.” Seeing 0.02 on one test and 0.03 on the next can trigger alarm, even though both values are within the noise range of the assay and neither approaches any clinical threshold. If you find yourself fixating on small movements at the bottom of the scale, it’s worth discussing with your oncologist whether the ultrasensitive assay is genuinely adding useful information to your care, or whether a standard assay with a slightly higher detection limit might give you the monitoring you need with less anxiety-inducing granularity. Some men benefit from the extra precision; others are better served by a test that simply reports “undetectable” and lets them get on with their lives.